SKYRIZI PRODUCT FACT SHEET

INDICATIONS[1]

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

150 mg/mL Single-dose prefilled syringe

150 mg/mL Single-dose Pen

Images not shown to scale.

PRODUCT OVERVIEW[1]

Dosage and administration[1]	• Recommended dosage: 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter
Packaging[1]	• 150 mg/mL single-dose Pen (carton of 1) • 150 mg/mL single-dose prefilled syringe (carton of 1)
Storage and handling[1]	• Store SKYRIZI in a refrigerator at 2°C to 8°C (36°F to 46°F) • Do not freeze SKYRIZI • Do not shake SKYRIZI • Keep SKYRIZI prefilled pens and prefilled syringes in the original cartons to protect from light • SKYRIZI is not made with natural rubber latex
Shipping case dimensions[2]	• Syringe: 5.29" x 2.50" x 1.28" • Pen: 7.31" x 2.17" x 1.70"
Weight[2]	• Syringe: 0.14 lb • Pen: 0.26 lb
WAC[1,2]*	• $18,272.79
NDC number[1]	• 150 mg/mL single-dose Pen (carton of 1): 0074-2100-01 • 150 mg/mL single-dose prefilled syringe (carton of 1): 0074-1050-01
Potential ICD-10-CM codes[3]	• L40 Psoriasis • L40.50 Arthropathic psoriasis, unspecified • L40.9 Psoriasis, unspecified

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; NDC=national drug code; WAC=wholesale acquisition cost.

*WAC is the price for the drug submitted to certain pricing compendia in January 2022 for publication and does not include prompt-pay discounts or other discounts, rebates, or reductions in price. The actual price paid by wholesalers and other customers and retail price paid by customers at a retail pharmacy.

Safety Considerations[1]

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves.
Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI.
Avoid use of live vaccines in SKYRIZI patients.

Please see additonal Important Safety Information on the next page.
Please see accompanying full Prescribing Information.

Skyrizi®
risankizumab-rzaa

Indications and Important Safety Information for SKYRIZI®(risankizumab-rzaa)[1]

Indications

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Important Safety Information

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see accompanying full Prescribing Information.

References: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc. **2.** Data on file, AbbVie Inc. **3.** Centers for Disease Control and Prevention. ICD-10-CM tabular list of diseases and injuries. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2021/icd10cm-tabular-p-2021.pdf. Accessed September 9, 2021.

abbvie

Skyrizi® risankizumab-rzaa

 US-SKZD-210633 January 2022